SecBot SecBot
8-K ·Filed Jun 1, 2026

RVRC

Revium Rx.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001213900-26-063235
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine CFO transition with an experienced replacement. Monitor for any strategic or financial changes in subsequent filings, but no immediate trading action warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final: all horizons settled through T+60d
RVRC ▼ -14.37% at T+60d
NEUTRAL call -14.37% · α vs SPY -15.60% · entry $1.67 → $1.43
Entry = T+0 close
Jun 1, 2026
via day close
T+1d
0.00%
call 0.00% · α -0.14%
$1.67
settled 5mo ago
T+5d
0.00%
call 0.00% · α +2.75%
$1.67
settled 5mo ago
T+20d
0.00%
call 0.00% · α +1.30%
$1.67
settled 4mo ago
T+60d
-14.37%
call -14.37% · α -15.60%
$1.43
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Revium Rx. announced the resignation of CFO Arie Gordashnikov effective May 27, 2026, with no reported disagreement. The Board simultaneously appointed Igor Bluvstein as CFO, effective immediately. Bluvstein brings CFO experience at Argent BioPharma and G Medical Innovations. The change appears orderly with a replacement in place.

Key Facts

  • CFO Arie Gordashnikov resigned effective May 27, 2026
  • Resignation not due to any disagreement with the company
  • Igor Bluvstein appointed as CFO effective same day
  • Bluvstein previously served as CFO at Argent BioPharma Ltd. (ASX: RGT) and G Medical Innovations Holdings Ltd. (NASDAQ: GMVD)
  • New CFO's compensation: monthly retainer of NIS17,000 plus VAT

Financial Impact

No material financial impact; CFO compensation is routine and immaterial

Risk Factors

  • Potential short-term disruption from CFO transition
  • New CFO's familiarity with Revium's operations and industry-specific challenges unknown

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-063235
Document: 0001213900-26-063235-index-headers.html0001213900-26-063235
Document: 0001213900-26-063235-index.html0001213900-26-063235
Document: 0001213900-26-063235.txt0001213900-26-063235
2 reports for RVRC
Performance horizon
Filters
Rows
Reports for RVRC, sortable and filterable
TypeNow
Jun 1, 2026
21w ago
8-K
NEUTRAL ★ 2/10
$1.67 $1.67· 0.00%▲ +1.30%$1.43 (−14.37%)
Apr 20, 2026
27w ago
8-K
NEUTRAL ★ 3/10
$1.67 $1.67· 0.00%▼ −4.92%$1.43 (−14.37%)
Showing 2 of 2

US Market Status

Market Closed · Opens in 4h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026